Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
7 "Glucagon-like peptide-1 receptor"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Drug/Regimen
Article image
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
Diabetes Metab J. 2023;47(3):394-404.   Published online March 6, 2023
DOI: https://doi.org/10.4093/dmj.2022.0221
  • 7,274 View
  • 290 Download
  • 7 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care.
Methods
This retrospective cohort study emulating a target trial included patient data from the multi-institutional Chang Gung Research Database in Taiwan. Totally, 33,021 patients with type 2 diabetes mellitus using SGLT2is and GLP1-RAs between 2016 and 2019 were identified. 3,249 patients were excluded due to missing demographics, age <40 years, prior use of any study drug, a diagnosis of retinal disorders, a history of receiving vitreoretinal procedure, no baseline glycosylated hemoglobin, or no follow-up data. Baseline characteristics were balanced using inverse probability of treatment weighting with propensity scores. DR diagnoses and vitreoretinal interventions served as the primary outcomes. Occurrence of proliferative DR and DR receiving vitreoretinal interventions were regarded as vision-threatening DR.
Results
There were 21,491 SGLT2i and 1,887 GLP1-RA users included for the analysis. Patients receiving SGLT2is and GLP-1 RAs exhibited comparable rate of any DR (subdistribution hazard ratio [SHR], 0.90; 95% confidence interval [CI], 0.79 to 1.03), whereas the rate of proliferative DR (SHR, 0.53; 95% CI, 0.42 to 0.68) was significantly lower in the SGLT2i group. Also, SGLT2i users showed significantly reduced risk of composite surgical outcome (SHR, 0.58; 95% CI, 0.48 to 0.70).
Conclusion
Compared to those taking GLP1-RAs, patients receiving SGLT2is had a lower risk of proliferative DR and vitreoretinal interventions, although the rate of any DR was comparable between the SGLT2i and GLP1-RA groups. Thus, SGLT2is may be associated with a lower risk of vision-threatening DR but not DR development.

Citations

Citations to this article as recorded by  
  • Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
    Samuel Igweokpala, Naheemot Olaoluwa Sule, Antonios Douros, Oriana H. Y. Yu, Kristian B. Filion
    Diabetes, Obesity and Metabolism.2024; 26(2): 721.     CrossRef
  • Association of sodium–glucose cotransporter‐2 inhibitors and the risk of retinal vascular occlusion: A real‐world retrospective cohort study in Taiwan
    Tzu‐Yi Lin, Eugene Yu‐Chuan Kang, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, Nan‐Kai Wang, Sunir J. Garg, Kuan‐Jen Chen, Je‐Ho Kang, Wei‐Chi Wu, Chi‐Chun Lai, Yih‐Shiou Hwang
    Diabetes/Metabolism Research and Reviews.2024;[Epub]     CrossRef
  • Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study
    Yu-Chi Su, Pei-Chun Hsieh, Edward Chia-Cheng Lai, Yu-Ching Lin
    Diabetes & Metabolism.2024; 50(2): 101522.     CrossRef
  • Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint
    Sarita Jacob, George I. Varughese
    Clinical Medicine.2024; 24(2): 100031.     CrossRef
  • Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
    Aikaterini Eleftheriadou, David Riley, Sizheng S. Zhao, Philip Austin, Gema Hernández, Gregory Y. H. Lip, Timothy L. Jackson, John P. H. Wilding, Uazman Alam
    Diabetologia.2024; 67(7): 1271.     CrossRef
  • Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study
    Karen M. Wai, Kapil Mishra, Euna Koo, Cassie Ann Ludwig, Ravi Parikh, Prithvi Mruthyunjaya, Ehsan Rahimy
    American Journal of Ophthalmology.2024; 265: 39.     CrossRef
  • Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
    Andrew J. Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
    Ophthalmology Retina.2024;[Epub]     CrossRef
  • Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
    Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Yih-Shiou Hwang
    Diabetes & Metabolism Journal.2023; 47(4): 573.     CrossRef
  • Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
    Jihee Ko, Sun Joon Moon
    Diabetes & Metabolism Journal.2023; 47(4): 571.     CrossRef
  • Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes
    Fu-Shun Yen, James Cheng-Chung Wei, Teng-Shun Yu, Yu-Tung Hung, Chih-Cheng Hsu, Chii-Min Hwu
    JAMA Network Open.2023; 6(12): e2348431.     CrossRef
Complications
Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni
Diabetes Metab J. 2022;46(6):901-911.   Published online April 12, 2022
DOI: https://doi.org/10.4093/dmj.2021.0314
  • 4,894 View
  • 271 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
In addition to the metabolic effects in diabetes, glucagon-like peptide 1 receptor (GLP-1R) agonists lead to a small but substantial increase in heart rate (HR). However, the GLP-1R actions on the autonomic nervous system (ANS) in diabetes remain debated. Therefore, this meta-analysis evaluates the effect of GLP-1R agonist on measures of ANS function in diabetes.
Methods
According to the Cochrane Collaboration and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, we conducted a meta-analysis considering clinical trials in which the autonomic function was evaluated in diabetic subjects chronically treated with GLP-1R agonists. The outcomes were the change of ANS function measured by heart rate variability (HRV) and cardiac autonomic reflex tests (CARTs).
Results
In the studies enrolled, HR significantly increased after treatment (P<0.001), whereas low frequency/high frequency ratio did not differ (P=0.410); no changes in other measures of HRV were detected. Considering CARTs, only the 30:15 value derived from lying-to-standing test was significantly lower after treatment (P=0.002), but only two studies reported this measurement. No differences in other CARTs outcome were observed.
Conclusion
The meta-analysis confirms the HR increase but seems to exclude an alteration of the sympatho-vagal balance due to chronic treatment with GLP-1R agonists in diabetes, considering the available measures of ANS function.

Citations

Citations to this article as recorded by  
  • Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
    Qianyi Li, Chunxuan Wu, Shiqun Sun, Lingchao Yang, Yanyan Li, Yixin Niu, Li Zhang, Wei Li, Ying Yu
    Journal of Diabetes.2024;[Epub]     CrossRef
  • A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
    Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
    Diabetes, Obesity and Metabolism.2024; 26(8): 3167.     CrossRef
  • Hormonal Gut–Brain Signaling for the Treatment of Obesity
    Eun Roh, Kyung Mook Choi
    International Journal of Molecular Sciences.2023; 24(4): 3384.     CrossRef
  • Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
    Yi-lin Huang, Xiao-zhuo Xu, Jing Liu, Pin-yao Wang, Xue-li Wang, Hong-lin Feng, Cheng-jiang Liu, Xu Han
    BMC Cardiovascular Disorders.2023;[Epub]     CrossRef
  • Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023
    Tiffany Lowe Clayton, Angela Fitch, Harold Edward Bays
    Obesity Pillars.2023; 8: 100083.     CrossRef
  • Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
    Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
    Diabetologia.2023; 66(10): 1832.     CrossRef
  • Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis
    Susumu Z. Sudo, Tadeu L. Montagnoli, Bruna de S. Rocha, Aimeé D. Santos, Mauro P. L. de Sá, Gisele Zapata-Sudo
    Biomedicines.2022; 10(12): 3258.     CrossRef
Short Communication
Drug/Regimen
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J. 2022;46(4):658-662.   Published online November 8, 2021
DOI: https://doi.org/10.4093/dmj.2021.0232
  • 65,535 View
  • 399 Download
  • 7 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated the real-world efficacy and safety of the combination of SGLT2i and GLP-1RA in patients with type 2 diabetes mellitus in Korea. The medical records of 104 patients who maintained the combination for at least 1 year were retrospectively reviewed. The change in glycosylated hemoglobin (HbA1c) after 6 months and 1 year of treatment was evaluated. The mean age was 51 years, and 41% were female. The mean baseline HbA1c, body mass index, and duration of diabetes were 9.0%, 28.8 kg/m2, and 11.7 years, respectively. Compared with baseline, the HbA1c decreased by 1.5% (95% confidence interval [CI], 1.27 to 1.74; P<0.001) after 6 months and by 1.4% (95% CI, 1.19 to 1.70; P<0.001) after 1 year. Over 1 year, the bodyweight change was −2.8 kg (95% CI, −4.21 to −1.47; P<0.001). The combination of SGLT2i and GLP-1RA is effective and tolerable in type 2 diabetes mellitus patients in real-world practice.

Citations

Citations to this article as recorded by  
  • Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
    Aftab Ahmad, Hani Sabbour
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome
    Fernando Cortés-Camacho, Oscar René Zambrano-Vásquez, Elena Aréchaga-Ocampo, Jorge Ismael Castañeda-Sánchez, José Guillermo Gonzaga-Sánchez, José Luis Sánchez-Gloria, Laura Gabriela Sánchez-Lozada, Horacio Osorio-Alonso
    Antioxidants.2024; 13(7): 768.     CrossRef
  • Hormonal Gut–Brain Signaling for the Treatment of Obesity
    Eun Roh, Kyung Mook Choi
    International Journal of Molecular Sciences.2023; 24(4): 3384.     CrossRef
  • All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
    David R. Riley, Hani Essa, Philip Austin, Frank Preston, Isatu Kargbo, Gema Hernández Ibarburu, Ramandeep Ghuman, Daniel J. Cuthbertson, Gregory Y. H. Lip, Uazman Alam
    Diabetes, Obesity and Metabolism.2023; 25(10): 2897.     CrossRef
  • The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Chen Li, Jie Luo, Mingyan Jiang, Keke Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
    Hwi Seung Kim, Woo Je Lee
    Diabetes & Metabolism Journal.2022; 46(4): 665.     CrossRef
  • Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
    Tomoyuki Kawada
    Diabetes & Metabolism Journal.2022; 46(4): 663.     CrossRef
  • Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
    Hwi Seung Kim, Yun Kyung Cho, Myung Jin Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Reviews
Complications
Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet
Vincenza Spallone
Diabetes Metab J. 2019;43(1):3-30.   Published online November 2, 2018
DOI: https://doi.org/10.4093/dmj.2018.0259
  • 17,239 View
  • 430 Download
  • 157 Web of Science
  • 163 Crossref
AbstractAbstract PDFPubReader   

The burden of diabetic cardiovascular autonomic neuropathy (CAN) is expected to increase due to the diabetes epidemic and its early and widespread appearance. CAN has a definite prognostic role for mortality and cardiovascular morbidity. Putative mechanisms for this are tachycardia, QT interval prolongation, orthostatic hypotension, reverse dipping, and impaired heart rate variability, while emerging mechanisms like inflammation support the pervasiveness of autonomic dysfunction. Efforts to overcome CAN under-diagnosis are on the table: by promoting screening for symptoms and signs; by simplifying cardiovascular reflex tests; and by selecting the candidates for screening. CAN assessment allows for treatment of its manifestations, cardiovascular risk stratification, and tailoring therapeutic targets. Risk factors for CAN are mainly glycaemic control in type 1 diabetes mellitus (T1DM) and, in addition, hypertension, dyslipidaemia, and obesity in type 2 diabetes mellitus (T2DM), while preliminary data regard glycaemic variability, vitamin B12 and D changes, oxidative stress, inflammation, and genetic biomarkers. Glycaemic control prevents CAN in T1DM, whereas multifactorial intervention might be effective in T2DM. Lifestyle intervention improves autonomic function mostly in pre-diabetes. While there is no conclusive evidence for a disease-modifying therapy, treatment of CAN manifestations is available. The modulation of autonomic function by SGLT2i represents a promising research field with possible clinical relevance.

Citations

Citations to this article as recorded by  
  • Rectal sensitivity correlated with gastrointestinal‐mediated glucose disposal, but not the incretin effect
    Sondre Meling, Erling Tjora, Heike Eichele, Rasmus B. Nedergaard, Filip K. Knop, Niels Ejskjaer, Siri Carlsen, Pål R. Njølstad, Christina Brock, Eirik Søfteland
    Endocrinology, Diabetes & Metabolism.2024;[Epub]     CrossRef
  • Glucose metabolism and autonomic function in healthy individuals and patients with type 2 diabetes mellitus at rest and during exercise
    Takuto Hamaoka, Urs A. Leuenberger, Rachel C. Drew, Matthew Murray, Cheryl Blaha, Jonathan Carter Luck, Lawrence I. Sinoway, Jian Cui
    Experimental Physiology.2024; 109(2): 214.     CrossRef
  • Quantification of lipoproteins by proton nuclear magnetic resonance spectroscopy (1H-NMRS) improves the prediction of cardiac autonomic dysfunction in patients with type 1 diabetes
    L. Nattero-Chávez, M. Insenser, N. Amigó, S. Samino, N. Martínez-Micaelo, B. Dorado Avendaño, A. Quintero Tobar, H. F. Escobar-Morreale, M. Luque-Ramírez
    Journal of Endocrinological Investigation.2024;[Epub]     CrossRef
  • Predictors of pacemaker requirement in patients with implantable loop recorder and unexplained syncope: A systematic review and meta‐analysis
    Moein Zangiabadian, Kiarash Soltani, Yasaman Gholinejad, Reyhane Yahya, Shayan Bastami, Mohammad Ali Akbarzadeh, Mohammad Sharifian Ardestani, Azadeh Aletaha
    Clinical Cardiology.2024;[Epub]     CrossRef
  • Impaired Cardiovagal Activity as a Link Between Hyperglycemia and Arterial Stiffness in Adults With Type 2 Diabetes Mellitus Among an Eastern Indian Population: A Cross-sectional Study
    Nibedita Priyadarsini, Devineni Likhitha, Madumathy Ramachandran, Kishore Kumar Behera
    Canadian Journal of Diabetes.2024; 48(3): 147.     CrossRef
  • No clear evidence of neuropathy among patients with high risk for the development of prediabetes/diabetes—a pilot study
    Anna E. Körei, Magdolna Békeffy, Adrienn Menyhárt, Karola Osgyán, Ildikó Istenes, Viktor J. Horváth, Péter Kempler
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Effects of Physical Cues on Stem Cell-Derived Extracellular Vesicles toward Neuropathy Applications
    Danyale Berry, Justice Ene, Aakash Nathani, Mandip Singh, Yan Li, Changchun Zeng
    Biomedicines.2024; 12(3): 489.     CrossRef
  • Oxidative Stress, Endothelial Dysfunction, and N-Acetylcysteine in Type 2 Diabetes Mellitus
    Xin Li, Junyong Zou, Aiping Lin, Jingshu Chi, Hong Hao, Hong Chen, Zhenguo Liu
    Antioxidants & Redox Signaling.2024; 40(16-18): 968.     CrossRef
  • High dose cholecalciferol supplementation causing morning blood pressure reduction in patients with type 1 diabetes mellitus and cardiovascular autonomic neuropathy
    João Felício, Lorena Moraes, Gabriela Lemos, Ícaro Souza, Giovana Vieira, Lilian Silva, Natércia Queiroz, Ana Carolina Souza, Franciane Melo, João Felício Abrahão Neto, Hana Britto, Manuela Lemos, Márcia Santos, Priscila Figueiredo, Ana Regina Motta, Meli
    Scientific Reports.2024;[Epub]     CrossRef
  • Transcutaneous vagal nerve stimulation for treating gastrointestinal symptoms in individuals with diabetes: a randomised, double-blind, sham-controlled, multicentre trial
    Ditte S. Kornum, Davide Bertoli, Huda Kufaishi, Anne-Marie Wegeberg, Tina Okdahl, Esben B. Mark, Katrine L. Høyer, Jens B. Frøkjær, Birgitte Brock, Klaus Krogh, Christian S. Hansen, Filip K. Knop, Christina Brock, Asbjørn M. Drewes
    Diabetologia.2024; 67(6): 1122.     CrossRef
  • Independent and interactive associations of heart rate and obesity with type 2 diabetes mellites: A population‐based study
    Tianxin Zhu, Qingyu Chen, Hongxing Chen, Lili You, Dan Liu, Xiaoyun Zhang, Feng Li, Hongshi Wu, Juying Tang, Diaozhu Lin, Kan Sun, Li Yan, Meng Ren
    Journal of Diabetes.2024;[Epub]     CrossRef
  • Bladder dysfunction in adolescents with type 1 diabetes
    Vinni Faber Rasmussen, Mathilde Thrysøe, Páll Karlsson, Mette Madsen, Esben Thyssen Vestergaard, Jens Randel Nyengaard, Astrid Juhl Terkelsen, Konstantinos Kamperis, Kurt Kristensen
    Journal of Pediatric Urology.2024;[Epub]     CrossRef
  • Genetic markers of cardiac autonomic neuropathy in the Kazakh population
    Nazira Bekenova, Ainur Sibagatova, Alisher Aitkaliyev, Tamara Vochshenkova, Balzhan Kassiyeva, Valeriy Benberin
    BMC Cardiovascular Disorders.2024;[Epub]     CrossRef
  • Acompanhamento e rastreamento de pacientes com Diabetes Mellitus Tipo 2 em uma unidade de saúde: prevenção de complicações macro e microvasculares
    Maria Helena Cordeiro de Oliveira, Milena Nunes Alves de Sousa
    Cuadernos de Educación y Desarrollo.2024; 16(5): e4145.     CrossRef
  • POST-TRAUMATIC STRESS DISORDER, INSOMNIA, HEART RATE VARIABILITY AND METABOLIC SYNDROME (NARRATIVE REVIEW)
    Alexandr Serhiyenko, Myroslav Baitsar, Volodymyr Sehin, Ludmila Serhiyenko, Vitaliy Kuznets, Victoria Serhiyenko
    Proceeding of the Shevchenko Scientific Society. Medical Sciences.2024;[Epub]     CrossRef
  • Determinants of orthostatic hypotension in type 2 diabetes: is cardiac autonomic neuropathy the main factor?
    Ilenia D'Ippolito, Myriam Angelica Carlucci, Cinzia D'Amato, Davide Lauro, Vincenza Spallone
    Endocrine Practice.2024;[Epub]     CrossRef
  • New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized Trial
    Sofie Hecquet, Søren Ballegaard, Ebbe Eldrup, Christian Hansen, Tine Hansen, Gitte Harboe, Peter Rossing, Caroline Pichat, Torquil Watt, Finn Gyntelberg, Nanna Ørsted, Jens Faber
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 2519.     CrossRef
  • Mortality risk factors in newly diagnosed diabetic cardiac autonomic neuropathy
    Bruce A. Chase, Sylwia Pocica, Roberta Frigerio, Katerina Markopoulou, Demetrius M. Maraganore, Navamon Aunaetitrakul, Alexander Epshteyn, Alexandru C. Barboi
    Clinical Autonomic Research.2023; 33(6): 903.     CrossRef
  • Autonomic symptoms and associated factors in patients with chronic heart failure
    Hellen Da Silva, Sofie Pardaens, Marc Vanderheyden, Johan De Sutter, Heleen Demeyer, Michel De Pauw, Laurent Demulier, Jan Stautemas, Patrick Calders
    Acta Cardiologica.2023; 78(2): 203.     CrossRef
  • Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
    Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
    Diabetologia.2023; 66(10): 1832.     CrossRef
  • Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and diagnostic test findings
    Eleonora Galosi, Luca Leonardi, Pietro Falco, Giuseppe Di Pietro, Alessandra Fasolino, Nicoletta Esposito, Caterina Leone, Giulia Di Stefano, Maurizio Inghilleri, Marco Luigetti, Antonini Giovanni, Andrea Truini
    Amyloid.2023; 30(1): 59.     CrossRef
  • In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross‐sectional 68 Ga‐RGD‐PET study
    Jens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, Philip Hasbak, Lene Holmvang, Christian Stevns Hansen, Bernt Johan von Scholten, Marie Frimodt‐Møller, Peter Rossing, Tine Willum Hansen, Andreas Kjaer, Rasmus Sejersten Ripa
    Diabetic Medicine.2023;[Epub]     CrossRef
  • Cardiac innervations in diabetes mellitus—Anatomical evidence of neuropathy
    Natalija Filipović, Maja Marinović Guić, Vana Košta, Katarina Vukojević
    The Anatomical Record.2023; 306(9): 2345.     CrossRef
  • Clinical Predictors of Pacing Device Implantation in Implantable Cardiac Monitor Recipients for Unexplained Syncope
    Reina Tonegawa-Kuji, Yuko Y. Inoue, Michikazu Nakai, Koshiro Kanaoka, Yoko Sumita, Yuichiro Miyazaki, Akinori Wakamiya, Keiko Shimamoto, Nobuhiko Ueda, Kenzaburo Nakajima, Naoya Kataoka, Mitsuru Wada, Kenichiro Yamagata, Kohei Ishibashi, Koji Miyamoto, Sa
    CJC Open.2023; 5(4): 259.     CrossRef
  • Cardiovascular autonomic reflex tests using a handheld device in the diagnosis of cardiovascular autonomic neuropathy in patients with schizophrenia
    Laura Blok-Husum, Milka Ane Rank Brcelic, Hanin Kawa Farman Kawal Bassi, Svend Eggert Jensen, Rene Ernst Nielsen, Kristian Kragholm, Jesper Fleischer, Esben Laugesen, Christoffer Polcwiartek
    American Heart Journal Plus: Cardiology Research and Practice.2023; 26: 100252.     CrossRef
  • Causal association between vitamin D and diabetic neuropathy: a Mendelian randomization analysis
    Wei Huang, Lei Gu, Jingwen Wang, Yiqi Wang, Fangzheng Cao, Tianyu Jin, Yifan Cheng
    Endocrine.2023; 80(2): 328.     CrossRef
  • Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
    Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis
    Life.2023; 13(2): 497.     CrossRef
  • Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes
    Lía Nattero-Chávez, María Insenser, Alejandra Quintero Tobar, Elena Fernández-Durán, Beatriz Dorado Avendaño, Tom Fiers, Jean-Marc Kaufman, Manuel Luque-Ramírez, Héctor F. Escobar-Morreale
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Early Gastrointestinal Neuropathy Assessed by Wireless Motility Capsules in Adolescents with Type 1 Diabetes
    Vinni Faber Rasmussen, Mathilde Thrysøe, Páll Karlsson, Esben Thyssen Vestergaard, Kurt Kristensen, Ann-Margrethe Rønholt Christensen, Jens Randel Nyengaard, Astrid Juhl Terkelsen, Christina Brock, Klaus Krogh
    Journal of Clinical Medicine.2023; 12(5): 1925.     CrossRef
  • Heart rate variability in people with metabolic syndrome
    Kostiantyn Apykhtin, Svitlana Drozdovska, Olha Hurenko, Anastasiia Nahorna, Anatoly Pisaruk, Yuliia Panchenko, Olena Andrieieva
    Ageing & Longevity.2023; (1 2023): 1.     CrossRef
  • Heart rate variability in people with metabolic syndrome
    Kostiantyn Apykhtin, Svitlana Drozdovska, Olha Hurenko, Anastasiia Nahorna, Anatoly Pisaruk, Yuliia Panchenko, Olena Andrieieva
    JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE.2023; (1 2023): 1.     CrossRef
  • Potential of electronic devices for detection of health problems in older adults at home: A systematic review and meta-analysis
    Yu-ting Cao, Xin-xin Zhao, Yi-ting Yang, Shi-jie Zhu, Liang-dong Zheng, Ting Ying, Zhou Sha, Rui Zhu, Tao Wu
    Geriatric Nursing.2023; 51: 54.     CrossRef
  • Diabetes mellitus in der Akut- und Notfallmedizin
    Leo Benning, Julian Krehl, Felix Patricius Hans
    Notfallmedizin up2date.2023; 18(01): 45.     CrossRef
  • Correlation between Heart rate recovery and Left Atrial phasic functions evaluated by 2D speckle-tracking Echocardiography after Acute Myocardial infarction
    Behruz Mashayekhi, Reza Mohseni-Badalabadi, Ali Hosseinsabet, Tahereh Ahmadian
    BMC Cardiovascular Disorders.2023;[Epub]     CrossRef
  • Pancreatic sympathetic innervation disturbance in type 1 diabetes
    Senlin Li, Huimin Yuan, Keshan Yang, Qing Li, Ming Xiang
    Clinical Immunology.2023; 250: 109319.     CrossRef
  • A Nonrandomized Trial of the Effects of Passive Simulated Jogging on Short-Term Heart Rate Variability in Type 2 Diabetic Subjects
    Jose A. Adams, Jose R. Lopez, Veronica Banderas, Marvin A. Sackner, Mark Yorek
    Journal of Diabetes Research.2023; 2023: 1.     CrossRef
  • Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review
    Jasmine KaiLi Goh, Leroy Koh
    Diabetology International.2023; 14(3): 224.     CrossRef
  • Autonomic neuropathic symptoms in patients with diabetes: practical tools for screening in daily routine
    Ana Raquel Souza de Azevedo Vieira, Lara Benigno Porto-Dantas, Flaviene Alves do Prado Romani, Patrícia Souza Carvalho, Rodica Pop-Busui, Hermelinda Cordeiro Pedrosa
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • “Arterial stiffness is not associated with changes in the circadian pattern of blood pressure in patients with type 1 diabetes mellitus and cardiovascular autonomic dysfunction”
    Lía Nattero-Chávez, Ane Bayona Cebada, Elena Fernández-Durán, Alejandra Quintero Tobar, Beatriz Dorado Avendaño, Héctor Escobar-Morreale, Manuel Luque-Ramírez
    Diabetes and Vascular Disease Research.2023; 20(3): 147916412311736.     CrossRef
  • Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy (DSPN)
    Sanjeev Sharma, Gerry Rayman
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum
    Jens Faber, Søren Ballegaard, Nanna Ørsted, Ebbe Eldrup, Benny Karpatschof, Finn Gyntelberg, Sofie Korsgaard Hecquet, Albert Gjedde
    Frontiers in Neuroscience.2023;[Epub]     CrossRef
  • Functional status associated with postural dizziness, but not postural hypotension, in older adults: a community-based study
    Hsiang-Ju Cheng, Zih-Jie Sun, Feng-Hwa Lu, Yi-Ching Yang, Chih-Jen Chang, Jin-Shang Wu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial
    Jens Christian Laursen, Viktor Rotbain Curovic, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Marie Frimodt‐Møller, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Hiddo J. L. Heerspink, Christian Stevns Hansen, Peter Ros
    Diabetes, Obesity and Metabolism.2023; 25(10): 3064.     CrossRef
  • The Retinal Nerve Fiber Layer Thickness Is Associated with Systemic Neurodegeneration in Long-Term Type 1 Diabetes
    Christina Brock, Anne-Marie Wegeberg, Thomas Arendt Nielsen, Bassam Karout, Per M. Hellström, Asbjørn Mohr Drewes, Henrik Vorum
    Translational Vision Science & Technology.2023; 12(6): 23.     CrossRef
  • The Use of Empirical Mode Decomposition on Heart Rate Variability Signals to Assess Autonomic Neuropathy Progression in Type 2 Diabetes
    Sandra Cossul, Felipe Rettore Andreis, Mateus Andre Favretto, Jefferson Luiz Brum Marques
    Applied Sciences.2023; 13(13): 7824.     CrossRef
  • Topical Capsaicin for the Management of Painful Diabetic Neuropathy: A Narrative Systematic Review
    Brandon Goodwin, Maanas Chiplunkar, Ryan Salerno, Kylon Coombs, Umar Sannoh, Vrushank Shah, Nicholas Averell, Usmaan Al-Shebab, Deanna Janora
    Pain Management.2023; 13(5): 309.     CrossRef
  • Adynamic response to cold pain reflects dysautonomia in type 1 diabetes and polyneuropathy
    Thomas Arendt Nielsen, Søren Lundbye-Christensen, Yoanna Krasimirova Dimitrova, Sam Riahi, Birgitte Brock, Asbjørn Mohr Drewes, Christina Brock
    Scientific Reports.2023;[Epub]     CrossRef
  • Autonomic Nerve Function Tests in Patients with Diabetes
    Heung Yong Jin, Tae Sun Park
    The Journal of Korean Diabetes.2023; 24(2): 71.     CrossRef
  • Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies
    Mandeep Kaur, Sakshi Misra, Priyanka Swarnkar, Preeti Patel, Balak Das Kurmi, Ghanshyam Das Gupta, Amrita Singh
    Biochemical Pharmacology.2023; 215: 115723.     CrossRef
  • A three-month physical training program improves cardiovascular autonomic function in patients with metabolic syndrome with and without diabetes – a pilot study
    Anna Vágvölgyi, Judit Erzsébet Ábrahám, Éva Máthéné Köteles, Andrea Korom, Mária Barnai, Mónika Szűcs, Andrea Orosz, Péter Kempler, Adrienn Menyhárt, Attila Nemes, Tamás Várkonyi, István Baczkó, István Kósa, Csaba Lengyel
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Cardiovascular autonomic neuropathy in patients with type 2 diabetes with and without sensorimotor polyneuropathy
    Emil Peters, Mustapha Itani, Alexander G. Kristensen, Astrid Juhl Terkelsen, Thomas Krøigård, Hatice Tankisi, Troels S. Jensen, Nanna B. Finnerup, Sandra Sif Gylfadottir
    Journal of the Peripheral Nervous System.2023; 28(3): 450.     CrossRef
  • Cardiac Autonomic Neuropathy in Prediabetes: A Case-Control Study
    Pavan Gujjar, Y. S. Ravikumar, Lakshmi Nagendra, Hiya Boro, Saptarshi Bhattacharya
    Indian Journal of Endocrinology and Metabolism.2023; 27(4): 325.     CrossRef
  • Diabetic Neuropathies
    Melissa A. Elafros, Brian C. Callaghan
    CONTINUUM: Lifelong Learning in Neurology.2023; 29(5): 1401.     CrossRef
  • Determinants of the heart rate variability in type 1 diabetes mellitus
    Máté Hajdu, Konstandia Garmpis, Vivien Vértes, Noémi Vorobcsuk-Varga, Gergő Attila Molnár, László Hejjel, István Wittmann, Réka Faludi
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Effect of Exercise on Cardiovascular Autonomic Nervous Function in Patients with Diabetes: A Systematic Review
    Hidetaka Hamasaki
    Healthcare.2023; 11(19): 2668.     CrossRef
  • Influence of Fibrinogen/Albumin Ratio and Fibrinogen/Pre-Albumin Ratio on Cardiac Autonomic Neuropathy in Type 2 Diabetes
    Subei Zhao, Zheng Yang, Meng Yu, Linyu Xiang, Yuhuan Lv, Chunyan Tian, Rong Li
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3249.     CrossRef
  • In Ischemic Heart Disease, Reduced Sensitivity to Pressure at the Sternum Accompanies Lower Mortality after Five Years: Evidence from a Randomized Controlled Trial
    Søren Ballegaard, Jens Faber, Christian Selmer, Finn Gyntelberg, Svend Kreiner, Benny Karpatschof, Tobias Wirenfeldt Klausen, Åke Hjalmarson, Albert Gjedde
    Journal of Clinical Medicine.2023; 12(24): 7585.     CrossRef
  • Assessment of the relationship of systemic vascular dysfunction and cardiac autonomic neuropathy (CAN) with diabetic retinopathy
    KJ Hari Prakash, Sucheta Parija, Manisha Kar
    Journal of Family Medicine and Primary Care.2023; 12(12): 3236.     CrossRef
  • Autonomic Neuropathy in Ambulatory Type 2 Diabetes Mellitus Patients: A Single-arm Prospective, Observational Study
    Kaustav Saha, Shatavisa Mukherjee, Animesh Maiti, Santanu Kumar Tripathi
    Journal of the Practice of Cardiovascular Sciences.2023; 9(3): 178.     CrossRef
  • Insomnia and type 2 diabetes: how to help the patient. Modern view of a neurologist
    E. S. Akarachkova, O. V. Kotova, V. L. Klimov, D. I. Lebedeva
    FOCUS. Endocrinology.2023; 4(4): 12.     CrossRef
  • Carvedilol improves heart rate variability indices, biomarkers but not cardiac nerve density in streptozotocin-induced T2DM model of diabetic cardiac autonomic neuropathy
    Olawale Mathias Akinlade, Bamidele Owoyele, Olufemi Ayodele Soladoye
    Journal of Basic and Clinical Physiology and Pharmacology.2022; 33(2): 213.     CrossRef
  • Cardiovascular autonomic responses during head-up tilt test in newly diagnosed type 2 diabetes
    Esteban Jorge-Galarza, Margarita Torres-Tamayo, María del Rocío Martínez-Alvarado, Berenice Peña-Aparicio, Carmen González-Salazar, Juan Reyes-Barrera, Manuel Sierra-Beltrán, Erika Fajardo-Flores, Andrey Kostin, J. Antonio González-Hermosillo
    Irish Journal of Medical Science (1971 -).2022; 191(5): 2077.     CrossRef
  • Cardiovascular autonomic neuropathy and incident diabetic kidney disease in patients with type 2 diabetes
    Ji Eun Jun, Min Sun Choi, Jae Hyeon Kim
    Diabetes Research and Clinical Practice.2022; 184: 109181.     CrossRef
  • Kardiovaskuläre Risiken in der 4.–6. Lebensdekade mit Diabetes mellitus Typ 1
    Young Hee Lee-Barkey, Bernd Stratmann, Diethelm Tschöpe
    Der Diabetologe.2022; 18(2): 131.     CrossRef
  • Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants
    Francesca Romana Prandi, Isabella Evangelista, Domenico Sergi, Alberto Palazzuoli, Francesco Romeo
    Heart Failure Reviews.2022; 28(3): 597.     CrossRef
  • Comparison of Risk Assessment Strategies for Patients with Diabetes Mellitus and Stable Chest Pain: A Coronary Computed Tomography Angiography Study
    Jia Zhao, Shuo Wang, Pengyu Zhao, Yong Huo, Chunjie Li, Jia Zhou, Pawel Kleczynski
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
  • BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy
    Gidon J Bönhof, Gundega Sipola, Alexander Strom, Christian Herder, Klaus Strassburger, Birgit Knebel, Claudia Reule, Jan-Christoph Wollmann, Andrea Icks, Hadi Al-Hasani, Michael Roden, Oliver Kuss, Dan Ziegler
    BMJ Open.2022; 12(2): e057142.     CrossRef
  • Pragmatic Clinic-Based Investigation of Glycemic Variability in Patients With Type 1 Diabetes in Routine Clinical Practice and Its Association With Cardiovascular Autonomic Neuropathy: A Pilot Study
    Lucianne R.M. Tannus, Marilia B. Gomes
    Endocrine Practice.2022; 28(5): 465.     CrossRef
  • Longitudinal effects of one‐leg standing time on neuropathy outcomes in association with glycemic control in non‐elderly patients with type 2 diabetes
    Kazuhiro Sugimoto, Takashi Sozu, Takehiko Hoshino, Yuko Watanabe, Akira Tamura, Toshiro Yamazaki, Setsu Ohta, Susumu Suzuki, Takuro Shimbo
    Journal of Diabetes Investigation.2022; 13(6): 1039.     CrossRef
  • Thermal quantitative sensory testing as a screening tool for cardiac autonomic neuropathy in patients with diabetes mellitus
    Veronika Potockova, Sarka Mala, Lucie Hoskovcova, Vaclav Capek, Tomas Nedelka, Lucie Riedlbauchova, Daniel Baumgartner, Livie Mensova, Radim Mazanec
    Brain and Behavior.2022;[Epub]     CrossRef
  • Cardiovascular Autonomic Reflex Tests and 7 Heart Rate Variability Indices for Early Diagnosis of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Individuals
    Yeelen Ballesteros Atala, Mozânia Reis De Matos, Denise Engelbrecht Zantut-Wittmann, Alejandro Rosell Castillo, Daniele P Santos-Bezerra, Maria Lucia Correa-Giannella, Maria Cândida Ribeiro Parisi
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Design, synthesis, in vitro and in silico studies of naproxen derivatives as dual lipoxygenase and α-glucosidase inhibitors
    Asma Sardar, Obaid-ur-Rahman Abid, Saima Daud, M. Fakhar-e-Alam, Muhammad Hussnain Siddique, Muhammad Ashraf, Wardah Shahid, Syeda Abida Ejaz, M. Atif, Shafiq Ahmad, Sulman Shafeeq, Muhammad Afzal
    Journal of Saudi Chemical Society.2022; 26(3): 101468.     CrossRef
  • Clinical manifestations and evaluation of cardiac autonomic neuropathy in diabetes mellitus and metabolic syndrome
    L. S. Moshkhoeva, A. N. Barinov
    Neurology, Neuropsychiatry, Psychosomatics.2022; 14(2): 71.     CrossRef
  • The relationship between vitamin B12 levels and electrocardiographic ventricular repolarization markers
    Emre Yılmaz, Devrim Kurt, Aslı Vural, Ertan Aydın, Sencer Çamcı, Ercan Aydın
    Nutrición Hospitalaria.2022;[Epub]     CrossRef
  • The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double‐blinded, placebo‐controlled trial
    Suvanjaa Sivalingam, Emilie Hein Zobel, Christian S. Hansen, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Jacob K. Jensen, Tine W. Hansen, Peter Rossing
    Diabetes, Obesity and Metabolism.2022; 24(8): 1638.     CrossRef
  • Heart Rate Variability and Chronic Kidney Disease in Patients with Type 2 Diabetes
    Wei Shi, Jing Zhang, Dan Chen, Xiaolei Chen, Wei Duan, Hongmei Zhang, Fahd Abd Algalil
    Applied Bionics and Biomechanics.2022; 2022: 1.     CrossRef
  • Spectrum of cardiac autonomic neuropathy in patients with type 2 diabetes mellitus: A North India perspective
    PrativaPriyadarshani Sethi, Basavraj Jatteppanavar, Ravi Kant, Monika Pathania, MukeshChand Bairwa
    Journal of Cardio-diabetes and metabolic disorders.2022; 2(1): 23.     CrossRef
  • Cardiac Autonomic Dysfunction Is Associated With Risk of Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus
    Haixia Zeng, Jianmo Liu, Zheng Chen, Peng Yu, Jianping Liu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
    Gidon J. Bönhof, Christian Herder, Dan Ziegler
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Triglyceride glucose index is related with cardiac autonomic dysfunction in patients with metabolic syndrome
    Akif Serhat Balcıoğlu, Ekrem Aksu, Ahmet Çağrı Aykan
    Kardiologiia.2022; 62(6): 45.     CrossRef
  • Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes
    Sasha Smith, Pasha Normahani, Tristan Lane, David Hohenschurz-Schmidt, Nick Oliver, Alun Huw Davies
    Life.2022; 12(7): 1074.     CrossRef
  • Correlation between impaired hemodynamic response and cardiopulmonary fitness in middle-aged type 2 diabetes mellitus patients: a case–control study
    Jinjin Xie, Lianhua Yin, Jia Huang, Ying Xu, Yannan Chen, Jiawei Qin, Zhizhen Liu, Jing Tao
    European Journal of Applied Physiology.2022; 122(10): 2295.     CrossRef
  • Higher frequency of cardiovascular autonomic neuropathy in youth with type 2 compared to type 1 diabetes: Role of cardiometabolic risk factors
    Benjamin J. Varley, Megan L. Gow, Yoon Hi Cho, Paul Benitez‐Aguirre, Janine Cusumano, Alison Pryke, Albert Chan, Vallimayil Velayutham, Kim C. Donaghue, Maria E. Craig
    Pediatric Diabetes.2022; 23(7): 1073.     CrossRef
  • The role of protein kinase C in diabetic microvascular complications
    Deng Pan, Lin Xu, Ming Guo
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Dimitrios Patoulias, Alexandra Katsimardou, Nikolaos Fragakis, Christodoulos Papadopoulos, Michael Doumas
    Acta Diabetologica.2022; 60(1): 1.     CrossRef
  • Association between blood glucose levels and autonomic symptoms in Peru
    Gabriel Angeles-Zurita, Margorie Narro-Fuentes, Antonio Bernabe-Ortiz
    Primary Care Diabetes.2022; 16(5): 709.     CrossRef
  • Clinical scoring systems for the risk of cardiovascular autonomic neuropathy in type 1 and type 2 diabetes: A simple tool
    Marika Menduni, Cinzia D'Amato, Martina Leoni, Valentina Izzo, Mariateresa Staltari, Carla Greco, Andrea Abbatepassero, Giuseppe Seminara, Ilenia D'Ippolito, Davide Lauro, Vincenza Spallone
    Journal of the Peripheral Nervous System.2022; 27(4): 259.     CrossRef
  • Vagus nerve stimulation as a novel treatment for systemic lupus erythematous: study protocol for a randomised, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study
    Amanda Hempel Zinglersen, Ida Lynghøj Drange, Katrine Aagaard Myhr, Andreas Fuchs, Mogens Pfeiffer-Jensen, Christina Brock, Søren Jacobsen
    BMJ Open.2022; 12(9): e064552.     CrossRef
  • To the interpretation of frequency components of the heart rate variability
    N. V. Kuzmenko, V. A. Tsyrlin, M. G. Pliss
    Translational Medicine.2022; 9(3): 35.     CrossRef
  • Protein pyrrole adducts are associated with elevated glucose indices and clinical features of diabetic diffuse neuropathies
    Xiao Chen, Zhuyi Jiang, Lianjing Zhang, Wei Liu, Xiaohu Ren, Luling Nie, Desheng Wu, Zhiwei Guo, Weimin Liu, Xifei Yang, Yan Wu, Zhen Liang, Peter Spencer, Jianjun Liu
    Journal of Diabetes.2022; 14(10): 646.     CrossRef
  • Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
    Scott Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, Umme Rubab, Prathap Kanagala, Sizheng Steven Zhao, Anne Marshall, Emily Brown, Uazman Alam
    Clinical Therapeutics.2022; 44(10): 1394.     CrossRef
  • Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview
    Victoria A. Serhiyenko, Ludmila M. Serhiyenko, Volodymyr B. Sehin, Alexandr A. Serhiyenko
    Endocrine Regulations.2022; 56(4): 284.     CrossRef
  • Heart rate-corrected QT interval prolongation is associated with decreased heart rate variability in patients with type 2 diabetes
    Seon-Ah Cha
    Medicine.2022; 101(45): e31511.     CrossRef
  • Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
    Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni
    Diabetes & Metabolism Journal.2022; 46(6): 901.     CrossRef
  • Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis
    Susumu Z. Sudo, Tadeu L. Montagnoli, Bruna de S. Rocha, Aimeé D. Santos, Mauro P. L. de Sá, Gisele Zapata-Sudo
    Biomedicines.2022; 10(12): 3258.     CrossRef
  • The Relationship Between Orthostatic Hypotension and Vitamin D Deficiency in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Ece YİĞİT, Ridvan SİVRİTEPE, Dilay KARABULUT, Umut KARABULUT
    Online Türk Sağlık Bilimleri Dergisi.2022; 7(2): 313.     CrossRef
  • A study of heart rate variability in diabetic mellitus patients
    Srinivasa Jayachandra, Satyanath Reddy Kodidala
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 153.     CrossRef
  • Oxidative Damage and Anti-Inflammatory Activity of Myricetin from Berries in Streptozotocin-Induced Diabetic Rats
    Shuling Wang, Jing Zhang
    International Journal of Pharmacology.2022; 18(4): 753.     CrossRef
  • The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review
    Aikaterini Eleftheriadou, Scott Williams, Sarah Nevitt, Emily Brown, Rebecca Roylance, John P. H. Wilding, Daniel J. Cuthbertson, Uazman Alam
    Diabetologia.2021; 64(2): 288.     CrossRef
  • Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A cross‐sectional study
    Ernesto Maddaloni, Chiara Moretti, Rossella Del Toro, Sara Sterpetti, Maria Vittoria Ievolella, Gabriele Arnesano, Rocky Strollo, Silvia Irina Briganti, Luca D'Onofrio, Paolo Pozzilli, Raffaella Buzzetti
    Diabetic Medicine.2021;[Epub]     CrossRef
  • Effects of lunar cycle on fasting plasma glucose, heart rate and blood pressure in type 2 diabetic patients
    Sutanu Dutta Chowdhury, Subhasish Pramanik, Koena Bhattacharjee, Lakshmi Kanta Mondal
    Chronobiology International.2021; 38(2): 270.     CrossRef
  • Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
    Yaling Tang, Hetal Shah, Carlos Roberto Bueno Junior, Xiuqin Sun, Joanna Mitri, Maria Sambataro, Luisa Sambado, Hertzel C. Gerstein, Vivian Fonseca, Alessandro Doria, Rodica Pop-Busui
    Diabetes Care.2021; 44(1): 164.     CrossRef
  • Decreased glomerular filtration rate and increased albuminuria for identification of cardiovascular autonomic neuropathy in subjects with and without diabetes
    Ying-Chuen Lai, Hung-Yuan Li, Yi-Dier Jiang, Tien-Jyun Chang, Lee-Ming Chuang
    Autonomic Neuroscience.2021; 230: 102757.     CrossRef
  • Exposures influencing the developing central autonomic nervous system
    Sarah D. Schlatterer, Adre J. du Plessis
    Birth Defects Research.2021; 113(11): 845.     CrossRef
  • Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial
    Triantafyllos Didangelos, Eleni Karlafti, Evangelia Kotzakioulafi, Eleni Margariti, Parthena Giannoulaki, Georgios Batanis, Solomon Tesfaye, Kοnstantinos Kantartzis
    Nutrients.2021; 13(2): 395.     CrossRef
  • The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes
    Min Young Kim, Gyuri Kim, Ji Yun Park, Min Sun Choi, Ji Eun Jun, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
    Diabetes Technology & Therapeutics.2021; 23(6): 434.     CrossRef
  • Insulin resistance is independently associated with cardiovascular autonomic neuropathy in type 2 diabetes
    Yingshan Liu, Yu Peng, Jing Jin, Yanshan Chen, Chuna Chen, Zhenguo Chen, Haishan Huang, Lingling Xu
    Journal of Diabetes Investigation.2021; 12(9): 1651.     CrossRef
  • SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
    Vincenza Spallone, Paul Valensi
    Diabetes & Metabolism.2021; 47(4): 101224.     CrossRef
  • Reduction of Pressure Pain Sensitivity as Novel Non-pharmacological Therapeutic Approach to Type 2 Diabetes: A Randomized Trial
    Jens Faber, Ebbe Eldrup, Christian Selmer, Caroline Pichat, Sofie Korsgaard Hecquet, Torquil Watt, Svend Kreiner, Benny Karpatschof, Finn Gyntelberg, Søren Ballegaard, Albert Gjedde
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Relationship between cardiac autonomic neuropathy and cardio-metabolic risk profile in adults with type 1 diabetes
    M. Serdarova, R. Dimova, N. Chakarova, G. Grozeva, A. Todorova, T. Tankova
    Diabetes Research and Clinical Practice.2021; 174: 108721.     CrossRef
  • Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review
    Mar Sempere-Bigorra, Iván Julián-Rochina, Omar Cauli
    Journal of Personalized Medicine.2021; 11(3): 230.     CrossRef
  • Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
    Ditte S. Kornum, Astrid J. Terkelsen, Davide Bertoli, Mette W. Klinge, Katrine L. Høyer, Huda H. A. Kufaishi, Per Borghammer, Asbjørn M. Drewes, Christina Brock, Klaus Krogh
    Journal of Clinical Medicine.2021; 10(7): 1392.     CrossRef
  • Diabetic heart disease: A clinical update
    Jake Rajbhandari, Cornelius James Fernandez, Mayuri Agarwal, Beverly Xin Yi Yeap, Joseph M Pappachan
    World Journal of Diabetes.2021; 12(4): 383.     CrossRef
  • Novel and Emerging Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy
    Anne Marshall, Uazman Alam, Andreas Themistocleous, Nigel Calcutt, Andrew Marshall
    Clinical Therapeutics.2021; 43(9): 1441.     CrossRef
  • Cardiac Autonomic Neuropathy Is Not Reversed by Euglycemia Following Islet Transplantation
    Tejas Deshmukh, Peter Emerson, Patricia Anderson, Eddy Kizana, Philip J. O’Connell, D. Jane Holmes-Walker, James J.H. Chong
    Transplantation.2021; 105(5): 1125.     CrossRef
  • Attenuation of Muscle Mass and Density Is Associated With Poor Outcomes Among Patients Undergoing Major Gynecologic Surgery: A Retrospective Cohort Study
    Lu Che, Yan Zhang, Jiawen Yu, Li Xu, Yuguang Huang
    Anesthesia & Analgesia.2021; 132(6): 1692.     CrossRef
  • Association of Urinary N-Acetyl-β-D-Glucosaminidase with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Mellitus without Nephropathy
    Min Sun Choi, Ji Eun Jun, Sung Woon Park, Jee Hee Yoo, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Moon-Kyu Lee, Jae Hyeon Kim
    Diabetes & Metabolism Journal.2021; 45(3): 349.     CrossRef
  • Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
    Gordon Sloan, Dinesh Selvarajah, Solomon Tesfaye
    Nature Reviews Endocrinology.2021; 17(7): 400.     CrossRef
  • Heart Rate Variability as a Potential Non-invasive Marker of Blood Glucose Level
    L. R. Jarman, J. L. Elliott, T. Lees, R. Clifton-Bligh, A. M. Simpson, N. Nassif, S. Lal
    Human Physiology.2021; 47(2): 209.     CrossRef
  • Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
    Alice Duque, Mauro Felippe Felix Mediano, Andrea De Lorenzo, Luiz Fernando Rodrigues Jr
    World Journal of Diabetes.2021; 12(6): 855.     CrossRef
  • Gaussian process-based kernel as a diagnostic model for prediction of type 2 diabetes mellitus risk using non-linear heart rate variability features
    R. Shashikant, Uttam Chaskar, Leena Phadke, Chetankumar Patil
    Biomedical Engineering Letters.2021; 11(3): 273.     CrossRef
  • Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
    Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
    Advances in Therapy.2021; 38(8): 4195.     CrossRef
  • Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus
    Amanda Hempel Zinglersen, Katrine Kjær Iversen, Henrik Christian Bidstrup Leffers, Esben Laugesen, Jesper Fleischer, Søren Jacobsen
    Lupus Science & Medicine.2021; 8(1): e000507.     CrossRef
  • Impaired vagal adaptation to an exercise task in women with gestational diabetes mellitus versus women with uncomplicated pregnancies
    Marieta P. Theodorakopoulou, Areti Triantafyllou, Andreas Zafeiridis, Afroditi Κ. Boutou, Iris Grigoriadou, Evangelia Kintiraki, Stella Douma, Dimitrios G. Goulis, Konstantina Dipla
    Hormones.2021; 20(4): 753.     CrossRef
  • Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis
    Lucas Silva Sousa, Felipe de Araújo Nascimento, Juliano Rocha, Michelle Rocha-Parise
    International Journal of Cardiovascular Sciences.2021;[Epub]     CrossRef
  • Management of diabetic neuropathy
    Simona Cernea, Itamar Raz
    Metabolism.2021; 123: 154867.     CrossRef
  • Large fibre, small fibre and autonomic neuropathy in adolescents with type 1 diabetes: A systematic review
    Vinni Faber Rasmussen, Troels Staehelin Jensen, Hatice Tankisi, Páll Karlsson, Esben Thyssen Vestergaard, Kurt Kristensen, Jens Randel Nyengaard, Astrid Juhl Terkelsen
    Journal of Diabetes and its Complications.2021; 35(11): 108027.     CrossRef
  • Cardiovascular Risk Management in Type 1 Diabetes
    I. H. Teoh, P. Elisaus, J. D. Schofield
    Current Diabetes Reports.2021;[Epub]     CrossRef
  • Disturbances in the intraventricular conduction system in teenagers with type 1 diabetes. A pilot study
    Agnieszka Zubkiewicz-Kucharska, Anna Noczyńska, Małgorzata Sobieszczańska, Małgorzata Poręba, Joanna Chrzanowska, Rafał Poręba, Monika Seifert, Anna Janocha, Krystyna Laszki-Szcząchor
    Journal of Diabetes and its Complications.2021; 35(11): 108043.     CrossRef
  • Peripheral and Autonomic Neuropathy Status of Young Patients With Type 1 Diabetes Mellitus at the Time of Transition From Pediatric Care to Adult-Oriented Diabetes Care
    Anna Vágvölgyi, Ágnes Maróti, Mónika Szűcs, Csongor Póczik, Dóra Urbán-Pap, István Baczkó, Attila Nemes, Éva Csajbók, Krisztián Sepp, Péter Kempler, Andrea Orosz, Tamás Várkonyi, Csaba Lengyel
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Pancreatic exocrine insufficiency in diabetes is associated with autonomic dysfunction
    Dag André Sangnes, Elisabeth Sandvik Bergmann, Rose Marie Moss, Trond Engjom, Eirik Søfteland
    Scandinavian Journal of Gastroenterology.2021; 56(10): 1222.     CrossRef
  • Dependence of Heart Rate Variability Indices on the Mean Heart Rate in Women with Well-Controlled Type 2 Diabetes
    Adriana Robles-Cabrera, José M. Torres-Arellano, Ruben Fossion, Claudia Lerma
    Journal of Clinical Medicine.2021; 10(19): 4386.     CrossRef
  • Normative data on cardiovascular autonomic function in Greenlandic Inuit
    Marie Mathilde Bjerg Christensen, Christian Stevns Hansen, Jesper Fleischer, Dorte Vistisen, Stine Byberg, Trine Larsen, Jens Christian Laursen, Marit Eika Jørgensen
    BMJ Open Diabetes Research & Care.2021; 9(1): e002121.     CrossRef
  • What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs
    V. Spallone, C. Ciccacci, A. Latini, P. Borgiani, Karim Gariani
    Journal of Diabetes Research.2021; 2021: 1.     CrossRef
  • Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes
    O. E. Zinovyeva, T. M. Ostroumova, M. V. Koniashova, N. A. Gorbachev
    Neurology, Neuropsychiatry, Psychosomatics.2021; 13(5): 116.     CrossRef
  • Manifestazioni cliniche della neuropatia autonomica diabetica: valutazione dei sintomi
    Carla Greco, Chiara Pacchioni, Manuela Simoni
    L'Endocrinologo.2021; 22(6): 514.     CrossRef
  • Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review
    Xiaochun Zhang, Xue Yang, Bao Sun, Chunsheng Zhu
    Communications Biology.2021;[Epub]     CrossRef
  • The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls
    Jens Christian Laursen, Ida Kirstine B. Rasmussen, Emilie H. Zobel, Philip Hasbak, Bernt Johan von Scholten, Lene Holmvang, Rasmus S. Ripa, Christian S. Hansen, Marie Frimodt-Moeller, Andreas Kjaer, Peter Rossing, Tine W. Hansen
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Dependence of heart rate variability on indicators of type 1 diabetes mellitus control.
    N. O. Pertseva, O. V. Gurzhiy, K. I. Moshenets
    Medicni perspektivi (Medical perspectives).2020; 25(1): 88.     CrossRef
  • Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
    Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
    Diabetes, Obesity and Metabolism.2020; 22(9): 1527.     CrossRef
  • Diabetes mellitus and comorbidities: A bad romance
    Niki Katsiki, Dimitrios Tousoulis
    Hellenic Journal of Cardiology.2020; 61(1): 23.     CrossRef
  • Features of the glucose influence on the heart activity and the changes in the potentials of the stomach and the intestines at the heart insufficiency conditions
    V. V. Soltanov, L. M. Komarovskaya
    Doklady of the National Academy of Sciences of Belarus.2020; 63(6): 736.     CrossRef
  • Living Day to Day
    Gerald Kayingo, Virginia McCoy Hass
    Physician Assistant Clinics.2020; 5(2): 213.     CrossRef
  • Source specific PM2.5 associated with heart rate variability in the elderly with coronary heart disease: A community-based panel study
    Xi Chen, Bing Qiu, Qinpei Zou, Tian Qiu, Runkui Li, Ashley Truong, Yanmin Qi, Tao Liu, Limin Han, Tiebing Liu, Junrui Chang, Qi Sun, Ying Zhu, Dongqun Xu
    Chemosphere.2020; 260: 127399.     CrossRef
  • The Association of Autonomic Nervous System Function With Ischemic Stroke, and Treatment Strategies
    Mengxi Zhao, Ling Guan, Yilong Wang
    Frontiers in Neurology.2020;[Epub]     CrossRef
  • Cardiac diabetic autonomic neuropathy
    L. T. Akhmedzhanova, T. A. Belyakova, Yu. A. Podkovko, Yu. M. Shor
    Medical Council.2020; (21): 94.     CrossRef
  • Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions
    Liliana Espinoza, Carie R Boychuk
    Current Opinion in Pharmacology.2020; 54: 18.     CrossRef
  • Morning blood pressure surge is associated with autonomic neuropathy and peripheral vascular disease in patients with diabetes
    Federica Di Gennaro, Cinzia D’Amato, Roberto Morganti, Carla Greco, Susanna Longo, Diana Corradini, Davide Lauro, Vincenza Spallone
    Journal of Human Hypertension.2020; 34(7): 495.     CrossRef
  • The Compound Expression of HSP90 and INOS in the Testis of Diabetic Rats as Cellular and Pathologic Adverse Effects of Diabetes
    Ali Alsarhan, Kawther Faisal Amawi, Inas Saleh Al-Mazari, Hashem Abu Hurirah, Ahed J. Alkhatib
    Analytical Cellular Pathology.2020; 2020: 1.     CrossRef
  • Heart rate variability features from nonlinear cardiac dynamics in identification of diabetes using artificial neural network and support vector machine
    Yogender Aggarwal, Joyani Das, Papiya Mitra Mazumder, Rohit Kumar, Rakesh Kumar Sinha
    Biocybernetics and Biomedical Engineering.2020; 40(3): 1002.     CrossRef
  • Distal Symmetric and Cardiovascular Autonomic Neuropathies in Brazilian Individuals with Type 2 Diabetes Followed in a Primary Health Care Unit: A Cross-Sectional Study
    Mozania Reis de Matos, Daniele Pereira Santos-Bezerra, Cristiane das Graças Dias Cavalcante, Jacira Xavier de Carvalho, Juliana Leite, Jose Antonio Januario Neves, Sharon Nina Admoni, Marisa Passarelli, Maria Candida Parisi, Maria Lucia Correa-Giannella
    International Journal of Environmental Research and Public Health.2020; 17(9): 3232.     CrossRef
  • Awareness of hypoglycemia and spectral analysis of heart rate variability in type 1 diabetes
    Ticiana Paes, L. Clemente Rolim, Celso Sallum Filho, João Roberto de Sa, Sérgio A. Dib
    Journal of Diabetes and its Complications.2020; 34(8): 107617.     CrossRef
  • Is there cardiac autonomic neuropathy in prediabetes?
    Lindsay A. Zilliox, James W. Russell
    Autonomic Neuroscience.2020; 229: 102722.     CrossRef
  • Chronic Microvascular Complications in Prediabetic States—An Overview
    Angelika Baranowska-Jurkun, Wojciech Matuszewski, Elżbieta Bandurska-Stankiewicz
    Journal of Clinical Medicine.2020; 9(10): 3289.     CrossRef
  • Cardiac vagal tone as a novel screening tool to recognize asymptomatic cardiovascular autonomic neuropathy: Aspects of utility in type 1 diabetes
    Anne-Marie Wegeberg, Elin D Lunde, Sam Riahi, Niels Ejskjaer, Asbjørn M Drewes, Birgitte Brock, Rodica Pop-Busui, Christina Brock
    Diabetes Research and Clinical Practice.2020; 170: 108517.     CrossRef
  • Assessment of baroreceptor reflex sensitivity in young obese Saudi males at rest and in response to physiological challenges
    Abdullah N. AlShahrani, Lubna I. Al‐Asoom, Ahmed A. Alsunni, Nabil S. Elbahai, Talay Yar
    Physiological Reports.2020;[Epub]     CrossRef
  • The relationship between QT interval indices with cardiac autonomic neuropathy in diabetic patients: a case control study
    Maryam Vasheghani, Farzaneh Sarvghadi, Mohammad Reza Beyranvand, Habib Emami
    Diabetology & Metabolic Syndrome.2020;[Epub]     CrossRef
  • Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options
    Péter Bencsik, Kamilla Gömöri, Tamara Szabados, Péter Sántha, Zsuzsanna Helyes, Gábor Jancsó, Péter Ferdinandy, Anikó Görbe
    British Journal of Pharmacology.2020; 177(23): 5336.     CrossRef
  • Biological Activity of c-Peptide in Microvascular Complications of Type 1 Diabetes—Time for Translational Studies or Back to the Basics?
    Aleksandra Ryk, Aleksandra Łosiewicz, Arkadiusz Michalak, Wojciech Fendler
    International Journal of Molecular Sciences.2020; 21(24): 9723.     CrossRef
  • Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
    Aman Sharma, Shweta Mittal, Rohan Aggarwal, Meenakshi K. Chauhan
    Future Journal of Pharmaceutical Sciences.2020;[Epub]     CrossRef
  • Diabetic Autonomic Neuropathy: A Clinical Update
    Jugal Kishor Sharma, Anshu Rohatgi, Dinesh Sharma
    Journal of the Royal College of Physicians of Edinburgh.2020; 50(3): 269.     CrossRef
  • Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
    Niki Katsiki, Panagiotis Anagnostis, Kalliopi Kotsa, Dimitrios G. Goulis, Dimitri P. Mikhailidis
    Current Pharmaceutical Design.2019; 25(18): 2051.     CrossRef
  • Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
    Scott M. Williams, Aikaterini Eleftheriadou, Uazman Alam, Daniel J. Cuthbertson, John P. H. Wilding
    Diabetes Therapy.2019; 10(6): 1995.     CrossRef
Clinical Diabetes & Therapeutics
Article image
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi
Diabetes Metab J. 2017;41(6):423-429.   Published online December 19, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.6.423
  • 6,140 View
  • 75 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by  
  • Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
    Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
    European Journal of Pharmacology.2022; 933: 175269.     CrossRef
  • Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
    Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
    Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
  • Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
    Doo Soo Jeon
    Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11.     CrossRef
  • The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy.2019; 36(4): 798.     CrossRef
  • A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
    Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
    Diabetes Therapy.2019; 10(1): 5.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
    Hyun Jin Kim
    The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef
Islet Studies and Transplantation
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Suk Chon, Jean-François Gautier
Diabetes Metab J. 2016;40(2):99-114.   Published online April 25, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.2.99
  • 5,356 View
  • 113 Download
  • 45 Web of Science
  • 43 Crossref
AbstractAbstract PDFPubReader   

Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.

Citations

Citations to this article as recorded by  
  • GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes
    Joana Moreira Marques, Rute Nunes, Ana Margarida Carvalho, Helena Florindo, Domingos Ferreira, Bruno Sarmento
    ACS Pharmacology & Translational Science.2024; 7(5): 1650.     CrossRef
  • Bisphenol a accelerates the glucolipotoxicity-induced dysfunction of rat insulinoma cell lines: An implication for a potential risk of environmental bisphenol a exposure for individuals susceptible to type 2 diabetes
    Chengmeng Huang, Xiaolin Chen, Zedong Ouyang, Lingxue Meng, Jian Liu, Qihua Pang, Ruifang Fan
    Toxicology in Vitro.2024; 99: 105866.     CrossRef
  • Harnessing gut cells for functional insulin production: Strategies and challenges
    Kelvin Baafi, John C. March
    Biotechnology Notes.2023; 4: 7.     CrossRef
  • Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
    Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho
    Endocrinology and Metabolism.2023; 38(1): 1.     CrossRef
  • Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function
    Simon B. K. Jensen, Christian R. Juhl, Charlotte Janus, Julie R. Lundgren, Christoffer Martinussen, Christoffer Wiingaard, Cecilie Knudsen, Ruth Frikke‐Schmidt, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad, Signe S. Torekov
    Obesity.2023; 31(4): 977.     CrossRef
  • How do parasitic worms prevent diabetes? An exploration of their influence on macrophage and β-cell crosstalk
    Inah Camaya, Bronwyn O’Brien, Sheila Donnelly
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review
    Marah Alsayed Hasan, Stanley Schwartz, Victoria McKenna, Richard Ing
    Obesity Surgery.2023; 33(9): 2927.     CrossRef
  • Therapeutic Dilemma in Personalized Medicine
    Ehab S. EL Desoky
    Current Reviews in Clinical and Experimental Pharmacology.2022; 17(2): 94.     CrossRef
  • Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment
    Amar Abderrahmani, Cécile Jacovetti, Romano Regazzi
    Trends in Endocrinology & Metabolism.2022; 33(6): 378.     CrossRef
  • Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
    Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
    Diabetes, Obesity and Metabolism.2022; 24(12): 2353.     CrossRef
  • A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes
    Chih-Yuan Wang, Kuo-Chin Huang, Chia-Wen Lu, Chih-Hsun Chu, Chien-Ning Huang, Harn-Shen Chen, I-Te Lee, Jung-Fu Chen, Ching-Chu Chen, Chung-Sen Chen, Chang-Hsun Hsieh, Kai-Jen Tien, Hung-Yu Chien, Yu-Yao Huang, Jui-Pao Hsu, Guang-Tzuu Shane, Ai-Ching Chan
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4063.     CrossRef
  • Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study
    Tao Tao, Yi Zhang, Yu-Chen Zhu, Jia-Rong Fu, Yu-Ying Wang, Jie Cai, Jing-Yu Ma, Yu Xu, Yi-Ning Gao, Yun Sun, WuQiang Fan, Wei Liu
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1420.     CrossRef
  • The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study
    Tuccinardi Dario, Giorgino Riccardo, Pieralice Silvia, Watanabe Mikiko, Maggi Daria, Palermo Andrea, Defeudis Giuseppe, Fioriti Elvira, Pozzilli Paolo, Manfrini Silvia
    Acta Diabetologica.2021; 58(4): 411.     CrossRef
  • Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy
    E. V. Biryukova, I. A. Morozova, S. V. Rodionova
    Meditsinskiy sovet = Medical Council.2021; (21): 160.     CrossRef
  • Emerging Role of Caveolin-1 in GLP-1 Action
    Alessandra Puddu, Davide Maggi
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Improvements in HOMA indices and pancreatic endocrinal tissues in type 2-diabetic rats by DPP-4 inhibition and antioxidant potential of an ethanol fruit extract of Withania coagulans
    Heera Ram, Pramod Kumar, Ashok Purohit, Priya Kashyap, Suresh Kumar, Shivani Kumar, Garima Singh, Abdulaziz A. Alqarawi, Abeer Hashem, Elsayed Fathi Abd-Allah, Al-Bandari Fahad Al-Arjani, Bhim Pratap Singh
    Nutrition & Metabolism.2021;[Epub]     CrossRef
  • Chop / Ddit3 depletion in β cells alleviates ER stress and corrects hepatic steatosis in mice
    Jing Yong, Vishal S. Parekh, Shannon M. Reilly, Jonamani Nayak, Zhouji Chen, Cynthia Lebeaupin, Insook Jang, Jiangwei Zhang, Thazha P. Prakash, Hong Sun, Sue Murray, Shuling Guo, Julio E. Ayala, Leslie S. Satin, Alan R. Saltiel, Randal J. Kaufman
    Science Translational Medicine.2021;[Epub]     CrossRef
  • Assessment of Insulin Secretion and Insulin Resistance in Human
    So Young Park, Jean-François Gautier, Suk Chon
    Diabetes & Metabolism Journal.2021; 45(5): 641.     CrossRef
  • Targeted pharmacological therapy restores β-cell function for diabetes remission
    Stephan Sachs, Aimée Bastidas-Ponce, Sophie Tritschler, Mostafa Bakhti, Anika Böttcher, Miguel A. Sánchez-Garrido, Marta Tarquis-Medina, Maximilian Kleinert, Katrin Fischer, Sigrid Jall, Alexandra Harger, Erik Bader, Sara Roscioni, Siegfried Ussar, Annett
    Nature Metabolism.2020; 2(2): 192.     CrossRef
  • The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes
    Kristina S. Boye, Reema Mody, Maureen J. Lage, Raleigh E. Malik
    Clinical Therapeutics.2020; 42(9): 1812.     CrossRef
  • Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study
    Valentina K. Bayrasheva, Ivan Y. Pchelin, Vladimir A. Dobronravov, Alina Yu. Babenko, Svetlana G. Chefu, Ivan S. Shatalov, Volha N. Vasilkova, Natalia V. Hudiakova, Alexandra N. Ivanova, Pavel A. Andoskin, Elena N. Grineva
    Archives of Endocrinology and Metabolism.2020;[Epub]     CrossRef
  • A Phenotypic Screen Identifies Calcium Overload as a Key Mechanism of β-Cell Glucolipotoxicity
    Jennifer Vogel, Jianning Yin, Liansheng Su, Sharon X. Wang, Richard Zessis, Sena Fowler, Chun-Hao Chiu, Aaron C. Wilson, Amy Chen, Frederic Zecri, Gordon Turner, Thomas M. Smith, Brian DeChristopher, Heming Xing, Deborah M. Rothman, Xinming Cai, Alina Ber
    Diabetes.2020; 69(5): 1032.     CrossRef
  • Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice
    Gaëtan Prévost, Arnaud Arabo, Marie-Anne Le Solliec, Justine Bons, Marie Picot, Julie Maucotel, Hind Berrahmoune, Mouna El Mehdi, Saloua Cherifi, Alexandre Benani, Emmanuelle Nédélec, Moïse Coëffier, Jérôme Leprince, Anneli Nordqvist, Valéry Brunel, Pierr
    American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E147.     CrossRef
  • Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues
    Krister Bokvist, Ying Ding, William H. Landschulz, Vikram Sinha, Aleksandra Pastrak, Ruth M. Belin
    Diabetes, Obesity and Metabolism.2019; 21(7): 1606.     CrossRef
  • Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
    Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu
    Phytomedicine.2019; 62: 152946.     CrossRef
  • The future of new drugs for diabetes management
    Clifford J. Bailey, Caroline Day
    Diabetes Research and Clinical Practice.2019; 155: 107785.     CrossRef
  • Compact fluidic system for functional assessment of pancreatic islets
    Takeshi Hori, Kei Yamane, Takayuki Anazawa, Osamu Kurosawa, Hiroo Iwata
    Biomedical Microdevices.2019;[Epub]     CrossRef
  • Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
    Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Dong Seok Kim, Julie A. Mattison, Nigel H. Greig
    Scientific Reports.2019;[Epub]     CrossRef
  • Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
    Miaad Bader, Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot Glotfelty, Lital Rachmany, Hee Kyung Kim, Ho-Il Choi, Barry J. Hoffer, Chaim G. Pick, Nigel H. Greig, Dong Seok Kim
    Neurobiology of Disease.2019; 124: 439.     CrossRef
  • Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential
    N.M. Pathak, V. Pathak, V.A. Gault, S. McClean, N. Irwin, P.R. Flatt
    Biochemical Pharmacology.2018; 155: 264.     CrossRef
  • Human EndoC-βH1 β-cells form pseudoislets with improved glucose sensitivity and enhanced GLP-1 signaling in the presence of islet-derived endothelial cells
    Michael G. Spelios, Lauren A. Afinowicz, Regine C. Tipon, Eitan M. Akirav
    American Journal of Physiology-Endocrinology and Metabolism.2018; 314(5): E512.     CrossRef
  • Vildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practice
    Tatiana Yu. Demidova
    Problems of Endocrinology.2018; 64(5): 336.     CrossRef
  • Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss
    Paola Simeone, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Maria Teresa Guagnano, Armando Tartaro, Riccardo C. Bonadonna, Virginia Federico, Francesco Cipollone, Agostino Consoli, Francesca Santilli
    Nutrients.2018; 10(12): 1872.     CrossRef
  • Nutrient regulation of β-cell function: what do islet cell/animal studies tell us?
    R Carlessi, K N Keane, C Mamotte, P Newsholme
    European Journal of Clinical Nutrition.2017; 71(7): 890.     CrossRef
  • Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice
    You-Cheol Hwang, Ari Kim, Euna Jo, Yeoree Yang, Jae-Hyoung Cho, Byung-Wan Lee
    BMC Endocrine Disorders.2017;[Epub]     CrossRef
  • Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
    Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
    Diabetes, Obesity and Metabolism.2017; 19(5): 654.     CrossRef
  • The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
    Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Tatsuya Atsumi
    Cardiovascular Diabetology.2017;[Epub]     CrossRef
  • Recent Advances in Effect‐directed Enzyme Assays based on Thin‐layer Chromatography
    Sarah Bräm, Evelyn Wolfram
    Phytochemical Analysis.2017; 28(2): 74.     CrossRef
  • Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐
    Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang‐Wook Kim, Jeong Hyun Park, Kwa
    Diabetes, Obesity and Metabolism.2017; 19(5): 635.     CrossRef
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
  • Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
  • DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
    Eun Ju Bae
    Archives of Pharmacal Research.2016; 39(8): 1114.     CrossRef
  • Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet ß-cell Function in Severe Non-obese Diabetic Mice
    Li-rong Li, Jing Lu, Xiao-lei Jia, Hui Hui, Jie Zhang, Ying Liu, Wei-juan Cui, Qian-yue Xu, Da-long Zhu
    Molecular Medicine.2016; 22(1): 800.     CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang
Diabetes Metab J. 2015;39(3):177-187.   Published online June 15, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.3.177
  • 4,514 View
  • 48 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by  
  • Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
    Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
    Diabetes & Metabolism Journal.2024; 48(3): 418.     CrossRef
  • Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
    Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer